PSMA PET/CT Improves Outcomes in Prostate Cancer Recurrence

The landscape of treatment for recurrent prostate cancer is becoming increasingly precise, thanks to advances in imaging technology. Recent research suggests that staging with prostate-specific membrane androgen (PSMA) PET/CT scans can significantly impact treatment decisions and patient outcomes, allowing clinicians to tailor care more effectively. This is particularly true for men undergoing salvage radiotherapy after initial treatment with radical prostatectomy.

Precision in Recurrence: The Role of PSMA PET/CT

Between 20% and 40% of men who undergo radical prostatectomy for localized prostate cancer experience a biochemical recurrence – a rise in prostate-specific antigen (PSA) levels – within 10 years. Traditionally, identifying the location of this recurrence has been challenging, relying on imaging techniques like CT, MRI, and bone scans, which often lack the sensitivity to detect tiny deposits of cancer. PSMA PET/CT offers a significant improvement. It utilizes a radioactive tracer that binds to PSMA, a protein found on the surface of prostate cancer cells, allowing doctors to visualize even tiny areas of disease that were previously undetectable.

“It is helping precision medicine,” explains Jeremie Calais, MD, PhD, director of clinical research in the Ahmanson Translational Theranostics division at UCLA. “You witness more disease. It is more precise. You see disease earlier than before, and you are in a better position to impact disease progression.”

UCLA Study Highlights Impact on Treatment Strategies

Researchers at UCLA retrospectively analyzed data from 113 men who had undergone radical prostatectomy, experienced biochemical recurrence, and subsequently received salvage radiotherapy following a PSMA PET/CT scan. The study, published in the Journal of the National Comprehensive Cancer Network, revealed a strong correlation between the staging information obtained from the PSMA PET/CT scan and patient outcomes, specifically progression-free survival (PFS). Nikitas J, et al. J Natl Compr Canc Netw. 2026;doi:10.6004/jnccn.2025.7102

The median follow-up period was 59.4 months, with a median PFS of 49.2 months. Importantly, the study found that patients with no visible disease on the PSMA PET/CT scan (T0N0M0) had the lowest risk of death compared to those with more extensive disease (M1b-M1C). This suggests that in some cases, a more conservative approach – potentially avoiding aggressive treatment – may be appropriate when the scan shows no evidence of spread.

Tailoring Radiotherapy Based on Imaging Findings

The research as well highlighted the benefits of specific radiotherapy approaches based on the PSMA PET/CT staging. For men with TrN0M0 disease – indicating local recurrence without distant spread – whole pelvis radiotherapy significantly improved PFS. Conversely, for those with T0N0M0 disease, the benefit of whole pelvis radiotherapy was less pronounced. This suggests that the extent of radiotherapy should be tailored to the individual patient’s disease characteristics as revealed by the scan.

“Because this was a new technique, people tended to think that if you have nothing, Consider do nothing. We can de-escalate treatment management,” Calais said. “We found out that’s not the case. People are doing better when we irradiate the area where we are supposed to irradiate— even when there is no visible disease there.”

Androgen Deprivation Therapy and Metastasis-Directed Approaches

The study also examined the role of androgen deprivation therapy (ADT) and metastasis-directed radiotherapy. ADT was found to improve PFS in patients with nodal or distant metastasis, while prostate bed irradiation improved PFS for those with no PSMA-avid disease visible in the prostate bed. These findings reinforce the importance of a personalized treatment approach, incorporating ADT and targeted radiotherapy when appropriate.

Currently, approximately 67.3% of patients in the study received androgen deprivation therapy, a hormonal treatment used to unhurried the growth of prostate cancer. A smaller percentage, 12.4%, received metastasis-directed radiotherapy, which focuses radiation specifically on areas where the cancer has spread.

Limitations and Future Directions

The UCLA study is retrospective in nature, meaning it analyzed data collected after the fact. This type of study can be subject to biases and may not definitively prove cause-and-effect relationships. However, the findings provide valuable insights into the potential benefits of PSMA PET/CT-guided treatment decisions.

To further validate these findings, researchers at UCLA are currently conducting a prospective phase 3 clinical trial comparing outcomes in men who received PSMA PET/CT-guided salvage radiotherapy to those who did not. The results of this trial, expected later in 2026, will provide more definitive evidence on the impact of this advanced imaging technique. Read more about treatment intensification in advanced prostate cancer.

Implications for Patient Care and the Future of Prostate Cancer Management

The increasing utilize of PSMA PET/CT is transforming the way clinicians approach recurrent prostate cancer. By providing more accurate staging information, this technology allows for more personalized and effective treatment strategies. While further research is ongoing, the current evidence suggests that PSMA PET/CT is a valuable tool for improving outcomes for men facing this challenging diagnosis. Patients considering salvage radiotherapy after prostatectomy should discuss the potential benefits of PSMA PET/CT imaging with their oncologist.

For more information, Jeremie Calais, MD, PhD, can be reached at [email protected].

It’s important to remember that this is a rapidly evolving field, and treatment recommendations may change as new evidence emerges. Patients should stay informed and operate closely with their healthcare team to make the best decisions for their individual circumstances. You can find additional information and resources on prostate cancer from organizations like the American Cancer Society and the Prostate Cancer Foundation.